See inside every stock. Pro
WatchlistPro
S&P 5007,663▼ 1.21%Nasdaq26,009▼ 2.60%Dow Jones52,868▲ 0.02%Nasdaq 10028,959▼ 2.90%VIX19.03▲ 14.09%US Dollar101.62▼ 0.16%Gold spot4,093▼ 0.80%WTI103.44▲ 3.99%

iShares Biotechnology (IBB)

Healthcare ETF · iShares (BlackRock) · NASDAQ · 252 holdings
$209.54 ▼ -2.01 (0.95%)
At close · USD · Volume 2,165,928
Returns and riskCostIncomeDividend historyHoldingsX-Ray look-throughQuestions
52-week range
$153.25 – $217.12
Day's range
$206.80 – $212.77
1-year total return
+36.4%
This fund is also covered on our sister site ETFWinner.com, which has screener, overlap and comparison tools for ETFs.

IBB price chart

Daily, split-corrected, distributions markedEnd-of-day prices

IBB fund facts

FundiShares Biotechnology ETF
TickerIBB · NASDAQ
Issuer (by our rules)iShares (BlackRock)
Category (by our rules)Healthcare
Expense ratio0.44%
Holdings252
Net assets (fund, SEC)$9.1B
Yield (last 12 months)0.16%
DistributionsQuarterly
52-week range$153.25 – $217.12
Average volume (3 months)1,589,154
First price in our data9 Feb 2001
Issuer and category are assigned by StocksXray rules from the fund name. Expense ratio and net assets come from SEC filings; where a fund does not file them (for example grantor trusts) the field stays empty.

Returns and risk

1 month
−0.6%
3 months
+12.1%
6 months
+20.2%
Year to date
+24.3%
1 year
+36.4%
3 years a year
+21.7%
5 years a year
+6.0%
10 years a year
+9.2%
Volatility (1 year)
22.7%
Largest drop, last year
−9.6%
Largest drop in our data
−62.8%
Total return includes distributions, from end-of-day prices adjusted for splits and distributions, to 22 Oct 2026. Periods of 3 years and longer are annualised and shown only when the fund's history is long enough. Volatility is the standard deviation of daily returns over the last year, annualised. Past performance does not guarantee future results.

Cost: expense ratio

0.44% a year

On $10,000 invested that is about $44 a year in fund costs, taken out of the fund's assets.

Source: the fund's prospectus, as filed with the SEC on 22 Jul 2025 (risk/return summary data). Brokerage commissions and the bid-ask spread are separate costs.

Income: distributions

Paid, last 12 months
0.34 USD
Yield on today's price
0.16%
Frequency
Quarterly
Latest ex-date
15 Sep 2026
Full IBB dividend history →
Cash paid per current share (restated for share splits), before tax, from EODHD.

IBB top holdings

#HoldingWeight
1 BlackRock Funds III 11.66%
2 Vertex Pharmaceuticals, Inc. VRTX 8.08%
3 Amgen, Inc. AMGN 7.83%
4 Gilead Sciences, Inc. GILD 6.84%
5 Regeneron Pharmaceuticals, Inc. REGN 4.91%
6 Argenx SE 3.76%
7 Alnylam Pharmaceuticals, Inc. 3.12%
8 Natera, Inc. 2.89%
9 Revolution Medicines, Inc. 2.78%
10 Biogen, Inc. BIIB 2.47%
The top 10 make up 54.3% of the fund, out of 252 holdings.
Positions as of 30 Jun 2026, from the fund's Form N-PORT filed with the SEC. Public N-PORT holdings are quarter-end positions published about 60 days later, so they can be months old and the fund may have changed since.

X-Ray look-through

StocksXray scores 38% of IBB by weight (10 stocks in our S&P 500 coverage), so we can look inside the fund with our own numbers. The weighted average X-Ray Score of those stocks is 45 out of 100.

Undervalued 5%Fair 64%Overvalued 31%
Health Care 100%
Weights are the SEC holdings weights dated 30 Jun 2026; scores and fair-value labels are today's. Labels follow our fair-value method ("Undervalued" means fair value is more than 17.5% above the price) and are model estimates, not forecasts or advice. How the X-Ray Score works.

Similar Healthcare ETFs

ARKG ARK Genomic Revolution0.75% fee · +56.6% 1y XBI SPDR S&P Biotech0.35% fee · +41.9% 1y XLV Health Care Select Sector SPDR0.08% fee · +26.3% 1y IHI iShares U.S. Medical Devices0.38% fee · −11.3% 1y IYH iShares U.S. Healthcare0.38% fee · +25.6% 1y IHF iShares U.S. Healthcare Provid...0.38% fee · +20.6% 1y All healthcare ETFs →
Funds of the same category, nearest in trading size. Similar does not mean equivalent: check holdings and costs.

IBB: frequently asked questions

What is IBB?

IBB is the iShares Biotechnology ETF, issued by iShares (BlackRock), listed on NASDAQ. By our rules it is classed as "Healthcare". Its latest SEC filing lists 252 holdings.

What is the expense ratio of IBB?

IBB charges 0.44% a year, according to its prospectus filed with the SEC on 22 Jul 2025. On $10,000 that is about $44 a year in fund costs.

Does IBB pay dividends?

Yes. IBB paid 0.34 per share over the last 12 months, quarterly, a trailing yield of 0.16% on today's price. The latest ex-dividend date was 15 Sep 2026.

What does IBB hold?

The largest holdings in the latest SEC filing are BlackRock Funds III (11.7%), Vertex Pharmaceuticals, Inc. (8.1%), Amgen, Inc. (7.8%). The top 10 together make up 54.3% of the fund.

How has IBB performed?

Total return including distributions to 22 Oct 2026: 1 year +36.4%, 3 years +21.7% a year, 5 years +6.0% a year. Past performance does not guarantee future results.

How does StocksXray rate the stocks inside IBB?

We score 38% of the fund by weight (10 stocks) with our X-Ray Score: the weighted average is 45 out of 100. These are model estimates, not forecasts or advice.

Where the numbers come from

Prices and distributions end-of-day data from EODHD; returns are our own calculations from it.
Expense ratio and holdings SEC filings (prospectus risk/return data and Form N-PORT).
Category, issuer and leverage assigned by StocksXray rules from the fund name.
X-Ray look-through our scores applied to the SEC holdings.
Read the methodology →

StocksXray is for education only and is not financial advice or a recommendation to buy or sell anything. Past performance does not guarantee future results; funds can lose value.